EU pharma strategy could allow for shorter drug patents
A long-awaited proposal for the EU pharmaceutical strategy from the European Parliament doesn't directly reject the notion of changing the length of EU drug patents.
BY PETER THOMSEN eu correspondent for Watch medier, translated by daniel pedersen
The EU pharmaceutical strategy moves ahead without any clear objections – particularly pertaining to drug patent rights – from the EU Committee on the Environment, Public Health and Food Safety (ENVI), one of the negotiators behind the proposed strategy, Linea Søgaard-Lindell, reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
